Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Kyverna Therapeutics, Inc. Common Stock (KYTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: KYTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 86.34M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 298713 | Beta - | 52 Weeks Range 1.89 - 24.91 | Updated Date 04/1/2025 |
52 Weeks Range 1.89 - 24.91 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.33 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -46.93% | Return on Equity (TTM) -80.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -194415789 | Price to Sales(TTM) - |
Enterprise Value -194415789 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 3341.48 | Enterprise Value to EBITDA - | Shares Outstanding 43171600 | Shares Floating 22441075 |
Shares Outstanding 43171600 | Shares Floating 22441075 | ||
Percent Insiders 1.22 | Percent Institutions 85.04 |
Analyst Ratings
Rating 4.33 | Target Price 27.33 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kyverna Therapeutics, Inc. Common Stock
Company Overview
History and Background
Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. Founded in 2020, it leverages advancements in CAR T-cell technology to target specific immune cells that drive autoimmune disorders.
Core Business Areas
- Cell Therapy Development: Kyverna's primary focus is developing engineered T-cell therapies, specifically CAR T-cell therapies, for autoimmune diseases.
Leadership and Structure
Peter Maag is the CEO of Kyverna Therapeutics. The company has a scientific advisory board and is structured around research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- KYV-101: KYV-101 is Kyverna's lead product candidate, an anti-CD19 CAR T-cell therapy being developed for autoimmune diseases like lupus nephritis, systemic sclerosis, and multiple sclerosis. Market share data is not yet available, as the product is in clinical trials. Competitors include companies developing similar cell therapies for autoimmune diseases, such as Cartesian Therapeutics and Cabaletta Bio, and traditional therapies such as rituximab and belimumab.
Market Dynamics
Industry Overview
The autoimmune disease market is large and growing, with a significant unmet need for more effective and durable therapies. Cell therapies represent a promising new approach, but face challenges related to safety, efficacy, and manufacturing scalability.
Positioning
Kyverna is positioned as an innovator in the cell therapy space for autoimmune diseases, focusing on developing CAR T-cell therapies with the potential for long-term disease remission.
Total Addressable Market (TAM)
The total addressable market for autoimmune disease therapies is estimated to be over $100 billion. Kyverna is targeting a segment of this market with its cell therapy approach.
Upturn SWOT Analysis
Strengths
- Novel CAR T-cell technology
- Experienced leadership team
- Focus on a large and underserved market
- Strong preclinical and early clinical data
Weaknesses
- Early stage clinical development
- High manufacturing costs associated with cell therapies
- Potential safety concerns associated with CAR T-cell therapy
- Reliance on single lead product candidate
Opportunities
- Expand clinical trials to additional autoimmune diseases
- Develop next-generation CAR T-cell technologies
- Partner with pharmaceutical companies for commercialization
- Secure regulatory approvals for KYV-101
Threats
- Competition from other cell therapy companies
- Failure to demonstrate efficacy or safety in clinical trials
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- CRTX
- CABA
Competitive Landscape
Kyverna competes with other cell therapy companies and traditional pharmaceutical companies in the autoimmune disease market. Its competitive advantage lies in its novel CAR T-cell technology and focus on specific autoimmune indications.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is defined by the company's advancement through pre-clinical and clinical trials since its founding.
Future Projections: Future growth is dependent on the success of KYV-101 in clinical trials, potential regulatory approvals, and commercialization efforts.
Recent Initiatives: Recent initiatives include enrollment and advancement of KYV-101 trials in lupus nephritis, systemic sclerosis, and multiple sclerosis.
Summary
Kyverna Therapeutics is a promising but high-risk, high-reward clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases. Its lead product candidate, KYV-101, has shown encouraging early clinical data. Key risks include clinical trial failures, regulatory hurdles, and competition from other cell therapy companies. Kyverna's success depends on its ability to demonstrate the safety and efficacy of KYV-101 in pivotal clinical trials and secure regulatory approvals.
Similar Companies
- CRTX
- CABA
- EDIT
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Clinical trial data
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data for companies in this industry is limited and estimates were used.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kyverna Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Emeryville, CA, United States | ||
IPO Launch date 2024-02-08 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 112 | Website https://kyvernatx.com |
Full time employees 112 | Website https://kyvernatx.com | ||
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.